Evidence map›Paper›PMID 33681172›Full record

ArticleFrontiers in bioengineering and biotechnology2021

Encapsulation of Andrographolide in poly(lactide-co-glycolide) Nanoparticles: Formulation Optimization and

Bukola A Oseni, Chukwuemeka P Azubuike, Omotunde O Okubanjo, Cecilia I Igwilo, Jayanth Panyam

Open access · goldAbstract read
In one paragraph

Article in Frontiers in bioengineering and biotechnology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
8.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Development and Optimization ofPharmaceutics · 2024
    Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Molecules (Basel, Switzerland) · 2022
    Review
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Bukola A OseniDepartment of Pharmaceutics and Pharmaceutical Technology, University of Lagos, Lagos, Nigeria.
Chukwuemeka P AzubuikeDepartment of Pharmaceutics and Pharmaceutical Technology, University of Lagos, Lagos, Nigeria.
Omotunde O OkubanjoDepartment of Pharmaceutics and Pharmaceutical Technology, University of Lagos, Lagos, Nigeria.
Cecilia I IgwiloDepartment of Pharmaceutics and Pharmaceutical Technology, University of Lagos, Lagos, Nigeria.
Jayanth PanyamDepartment of Pharmaceutics, University of Minnesota, Minneapolis, MN, United States.
University of Lagos · NGTemple University · US

Funding

Cancer Stem Cell-Targeted, Silicate Prodrug Nanoparticles to Combat RecurrenceR01EB019893 · NIBIB · UNIVERSITY OF MINNESOTA · PI HOYE, THOMAS R., PANYAM, JAYANTH · 2017 to 2020
$1.3M
NIBIB NIH HHS R01 EB019893
6 · The paper itself

Abstract

Andrographolide is a potential chemopreventive and chemotherapeutic agent that suffers from poor aqueous solubility. Encapsulation in poly(lactide-co-glycolide) (PLGA) nanoparticles can overcome solubility issues and enable sustained release of the drug, resulting in improved therapeutic efficacy. In this study, andrographolide was encapsulated in PLGA nanoparticles via emulsion solvent evaporation technique. Effect of various formulation parameters including polymer composition, polymer molecular weight, polymer to drug ratio, surfactant concentration and the organic solvent used on nanoparticle properties were investigated. A selected formulation was used to determine the effect of encapsulation in nanoparticles on andrographolide's

Indexed as

andrographolidebreast cancerformulation optimizationnanoparticlespoly(lactide-co-glycolide)

Identifiers

PMID33681172
PMCPMC7930629
OpenAlexW3130959884

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.